anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses ruminant rumen-protected lysine, which belongs to the technical field of animal nutrition. The rumen-protected lysine consists of a core and a shell, wherein the shell is rumen fat powder; and the core is a mixture of lysine serving as an active ingredient and accessories. The ruminant rumen-protected lysine comprises the following raw materials in percentages by mass: the lysine 32-48, the accessories 8-12 and the rumen fat powder 40 to 60. The invention also provides the production method of the ruminant rumen-protected lysine, which comprises the steps of pelletizing and coating. The ruminant rumen-protected lysine has a small particle size which averagely is 1.0 millimeter and consistent with a variation coefficient of 10 percent, has good liquidity and is convenient to use directly in production. The production process is simple and suitable for industrial production and the production cost is low.
Participants with crohn's disease (CD) or ulcerative colitis (UC) with no prior exposure to ustekinumab, at least 1 year of enrollment records immediately prior to the new use will be required. The information will be sourced from the Department of Defense (DoD) Electronic Health Records (EHR) database in the United States (US).
This is a randomised, double-blind, placebo controlled and parallel design trial. Participants will be randomized to either acupuncture (n=30) or placebo (n=30) using a 1:1 ratio. The permuted blocks with a block size of 2 will be used. Both groups will continue with their routine diabetes care. Primary outcome of HOMA-IR will be measured at the time of recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment. Secondary outcome of HRQOL will be measured at the time of recruitment (baseline), after completion of 5 sessions (week 3/4) and 10 sessions (week 7) of the treatment while outcomes of body mass index and waist circumference are measured at the time of recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment. Any adverse event will be recorded at every visit. The sequence generation and allocation will remain concealed from the patient and practitioner.
PROBLEM TO BE SOLVED: To obtain a water-in-oil type emulsified composition having extremely excellent temperature stability by adding a specific compound or its salt to a system using an organic-modified clay mineral as a emulsifier. SOLUTION: This water-in-oil type emulsified composition comprises an organic-modified clay mineral obtained by treating a water-swelling clay mineral which is one kind of colloidal water-containing aluminum silicate having three- layer structure of formula I (X is Al, etc.; Y is Mg, etc.; Z is K, etc.) with a quaternary ammonium salt type cationic surfactant of formula II (R1 is an alkyl, etc.; R2 is methyl, etc.; R3 and R4 are each an alkyl, etc.; X is halogen, etc.) and a nonionic surfactant, an amino acid or its salt, oil content and water, L-Arginine or its hydrochloride, L-glutamic acid or its sodium salt is preferably used as the amino acid or its salt. The formulation amount of the amino acid or its salt is preferably 0.01-10.0wt.%.
Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
The participants of the experimental group, in addition to the integral rehabilitation of the center will receive the training of the attention through NeuronUp APT. There will be 3 rehabilitation sessions of one hour a week for about a month and a half or two.
10-(g -Methylaminopropyl)-phenothiazine is prepared by treating 10-(g -dimethylaminopropyl)-phenothiazine with ethyl chloroformate in benzene solution to form 10-[g -(N-methyl-N-carbethoxyamino)-propyl]-phenothiazine, which is then hydrolysed with aqueous potassium hydroxide. Alternatively, 10-(g -chloropropyl)-phenothiazine may be reacted with methyl amine.  The product may be isolated in the form of its hydrochloride, and other acid addition salts are also referred to.ALSO:A therapeutic composition for the treatment of depressions (having reserpine-antagonistic and serotonin-antagonistic properties) is characterized by a content of the compound <FORM:0974379/A5-A6/1> or a non-toxic, pharmaceutically acceptable acid addition salt thereof, in admixture with at least one pharmaceutically acceptable carrier. Specified salts are the hydrochloride, hydrobromide, sulphate, nitrate, phosphate, methane sulphonate, ethane sulphonate, beta-hydroxyethane sulphonate, camphor sulphonate, ethane disulphonate, formate, acetate, propionate, butyrate, valerate, glycolate, lactate, gluconate, succinate, maleate, fumarate, malate, tartrate, citrate, benzoate, salicylate, gentisate, mandelate and 8-chlorotheophyllin.  Dosage units are dragees, tablets, capsules, suppositories or ampoules containing 10 to 200 mg. of active ingredient.  Tablets may have a sugar or lacquer coating and may be coloured.  Soft gelatine capsules contain the active ingredient with polyethylene oxides; hard gelatine capsules contain granules of the active material; suppositories contain the active material mixed with polyethylene oxide bases.  Injections comprise aqueous solutions of the active ingredient containing buffers such as citric acid to produce a pH of 3.5 to 5.0, preservatives and anti-oxidants such as formaldehyde sodium bisulphite, sodium bisulphite, sodium sulphite and ascorbic acid, a mixture of the last three being particularly effective.
Each patient agreeing to participate in the study will be distributed in the protocol group and will receive an angioscan according to the protocol in pre-operative and at the usual post-operative check-up within 3 months after the operation. The usual procedure, foresees an angioscanner with injection of contrast product and the measurement of the images is performed during a deep breath. In order to obtain a complete respiratory cycle, the study procedure foresees in addition to the usual procedure, an image measurement during a deep exhalation.
Lassa fever is a zoonotic infection endemic in West Africa and is spread by the Lassa virus, an arenavirus causing hemorrhagic fever. Up to 300,000 Lassa fever infections occur annually and while disease is often mild, in a subset of individuals disease is characterized by severe anemia, bleeding, encephalopathy, respiratory failure, shock, and high mortality. In some regions of West Africa, up to 15% of hospital admissions are secondary to Lassa fever, and an estimated 5,000 deaths occur annually. During epidemics of disease, case-fatality rates may reach as high as 50% in hospitalized patients. Approximately one-third of infected individuals will develop hearing loss regardless of disease severity, and in a proportion of patients, permanent deafness occurs.

Prevention of illness through vaccination is a critical goal in reducing the burden of disease from Lassa fever. There are currently no vaccines or therapeutics demonstrated to be efficacious in the prevention or treatment of Lassa fever. This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen. The antigen will be presented on a genetically modified and attenuated rabies vector expressing both the rabies glycoprotein (GP) antigen and the Lassa GPC. The inactivated chimeric virus is delivered with a toll-like receptor (TLR-4)-activating oil-in-water emulsion adjuvant. Studies using this vaccine administered as a prime-boost series in mice and non-human primates, and then challenged with Lassa virus demonstrated significant protection against Lassa fever. Given that the vaccine backbone is an attenuated and inactivated rabies virus expressing rabies GP, this vaccine will also be evaluated for immunogenicity against rabies virus.
PURPOSE: Genetic susceptibility to nonsyndromic renal cell carcinoma (RCC) remains poorly understood, especially for different histological subtypes, as does variations in genetic predisposition in different populations. The objectives of this study were to identify risk genes for RCC in the Canadian population, investigate their clinical significance, and evaluate variations in germline pathogenic variants (PVs) among patients with RCC across the globe.
MATERIALS AND METHODS: We conducted targeted sequencing of 19 RCC-related and 27 cancer predisposition genes for 960 patients with RCC from Canada and identified genes enriched in rare germline PVs in RCC compared with cancer-free controls. We combined our results with those reported for patients from Japan, the United Kingdom, and the United States to investigate PV variations in different populations. Furthermore, we evaluated the performance of referral criteria for genetic screening for including patients with rare PVs.
RESULTS: We identified 39 germline PVs in 56 patients (5.8%) from the Canadian cohort. Compared with cancer-free controls, PVs in CHEK2 (odds ratio [OR], 4.8 [95% CI, 2.7 to 7.9], P = 3.94 × 10-5) and ATM (OR, 4.5 [95% CI, 2.0 to 8.7], P = .016) were significantly enriched in patients with clear cell, whereas PVs in FH (OR, 215.1 [95% CI, 64.4 to 597.8], P = 6.14 × 10-9) were enriched in patients with non-clear cell RCCs. PVs in BRCA1, BRCA2, and ATM were associated with metastasis (P = .003). Comparative analyses showed an enrichment of TP53 PVs in patients from Japan, of CHEK2 and ATM in patients from Canada, the United States and the United Kingdom, and of FH and BAP1 in the United States.
CONCLUSION: CHEK2, ATM, and FH are risk genes for RCC in the Canadian population, whereas PVs in BRCA1/2 and ATM are associated with risk of metastasis. Globally, clinical guidelines for genetic screening in RCC fail to include more than 70% of patients with rare germline PVs.
The purpose of this research; The aim of this study is to measure the effect of the Persons With Disability Friendly Nursing Education Program developed based on the Story Theory on the empathic tendencies of senior nursing students towards persons with disability and their perceptions of competence of senior nursing students to care for persons with disability. In the research, a multi-stage evaluation design from mixed method research will be used. Focus group interviews will be conducted before and after the program in the qualitative dimension of the research, while the randomized controlled double-blind pretest-posttest control group experimental design will be used in the quantitative dimension. The data of the research will be collected in the Department of Nursing of the Faculty of Health Sciences of Ondokuz Mayis University in Samsun, Turkey. The program will be applied to nursing senior students in this department. Before the training program, focus group discussions will be held with nursing students, and the content of the training program will be created. The pre-test data of the study will be collected using an introductory information form questioning sociodemographic characteristics, Efficacy Perceptions Form for Caring for Persons with Disabilities, Empathic Tendency Scale and Achievement Test. A 2-week " Persons With Disability Friendly Nursing Education Program" will be applied to the experimental group. After the program, focus group discussions will be held with the students in the experimental group, and the program will be evaluated. Post-tests will be applied to the experimental and control groups 3 months after the program. Descriptive statistics, paired t-test, chi-square, Mann-Whitney U, Wilcoxon analysis will be used in the analysis of the data. Content analysis will be used in qualitative data analysis.
OBJECTIVE: This study aims to investigate how arthritis, including osteoarthritis and rheumatoid arthritis, affects the incidence of nocturia in adults aged 20-59.
METHODS: This study utilized data from the National Health and Nutrition Examination Survey from 2005 to 2020, involving 18 745 adults aged 20-59. Arthritis, including osteoarthritis and rheumatoid arthritis, was considered as the exposure factor, with nocturia as the outcome variable. We first compared the baseline characteristics of individuals with and without nocturia. The impact of arthritis on nocturia was assessed using weighted multivariate logistic regression models. To ensure the stability of the results, propensity score matching analysis and subgroup analyses were conducted.
RESULTS: The incidence of nocturia was approximately 22.31%, and the incidence of arthritis was about 15.32% (2871/18 745), with osteoarthritis accounting for 35.49% (1019/2871) and rheumatoid arthritis accounting for 20.20% (580/2871). Adjusted multivariate logistic regression analysis revealed that the risk of nocturia was increased by arthritis (odds ratio [OR] = 1.45, 95% confidence interval [CI]: 1.28-1.65, p < 0.0001), including osteoarthritis (OR = 1.45, 95% CI: 1.18-1.78, p < 0.001) and rheumatoid arthritis (OR = 1.51, 95% CI: 1.14-2.00, p = 0.004). After propensity score matching using nearest neighbor methods at a 1:1 ratio, this relationship still exists. Subgroup analyses showed no significant differences in the interactions between arthritis and the risk of nocturia across various factors, such as age, family income to poverty ratio, education level, body mass index, smoking status, hypertension, and diabetes. However, significant differences were observed across different sex groups and sleep trouble groups.
CONCLUSIONS: This study revealed that arthritis, including osteoarthritis and rheumatoid arthritis, increased the risk of nocturia in adults under the age of 60.
Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi'an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s "on" periods and 30s "off" periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs).
PURPOSE:To obtain the title cosmetic liquid and hand cream etc., in such a way that a melon extract produced using a juicer is incorporated with borax into a solution, which is mixed with a second solution prepared by dissolving butyl p-hydroxybenzoate in ethanol, and glycerin is added to the resulting mixture. CONSTITUTION:[1] (A) melon extract produced using a juicer, (B) borax, (C) ethanol, (D) glycerin and (E) butyl p-hydroxybenzoate are fully agitated into dissolution, and the mixture is then filtered. 4-6 weight times of purified water (based on the component A) is added to the resulting filtrate to obtain the objective cosmetic liquid. [2] Borax is dissolved in a melon extract into a solution, which is then mixed with a second solution prepared by dissolving butyl p-hydroxybenzoate in ethanol. The resultant solution is filtered, and the filtrate is mixed with a hydrophilic ointment followed by, finally, addition of glycerin and then sufficient agitation and mixing, thus obtaining the other objective hand cream. These cosmetics have excellent moisture retaining property and elasticity due to synergic effect of glycerin and the melon extract.
No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
It will be a randomised, assessor-blind controlled trial embedding both outcome and process evaluation, of the EMA/I CBT-I in conjunction with wearable sensors. The outcome evaluation will examine the treatment effect of EMA/I CBT-I compared with care-as-usual (CAU), whilst process evaluation will enhance the understanding of the causal assumptions that underpin EMA/I CBT-I to inform policy and clinical practice. 60 eligible participants will be randomly assigned to the EMA/I CBT-I group and CAU in a 1:1 allocation ratio. The participants in the EMA/I CBT-I group will receive 6 weeks of smartphone-based EMA/I CBT-I supported by a therapist. The trained therapist will prescribe EMI, provide personalised sleep advice, and adjust the treatment by dynamically adapting real-time rest-activity assessments collected using EMA and wearable devices. Assessments will be managed by an independent assessor (a research assistant) who is blind to group allocation at baseline, week 7 (1 week after treatment), and week 18 (12 weeks after treatment). The proposed study will follow the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) and will be registered on ClinicalTrials.gov to ensure compliance with study design and results reporting requirements. The treatment will be provided free of charge.
Arthritis is a common illness that affects joints and it may result in inflammation and pain. Even though arthritis usually affects older people, it can also affect children, adults, and both genders. Numerous arthritic mouse models have been developed but the CIA model of rheumatoid arthritis (RA) has received the most attention. With the use of steroids, DMARDs, and NSAIDs, therapy objectives such as reduced disease incidence and better pain management are achieved. Long-term usage of these therapeutic approaches may have negative side effects. Herbal medications are the source of several medicinal substances. Studies have explored the potential benefits of medicinal plants in treating RA. These benefits include up-regulating antioxidant potential, inhibiting cartilage degradation, down-regulating inflammatory cytokines such as NF-kB, IL-6, and TNF-α, and suppressing oxidative stress. In this review, we systematically discuss the role of traditional medicinal plants in rheumatoid arthritis (RA) disease treatment. The role of different medicinal plants such as Curcuma longa, Syzygium aromaticum, Zingiber officinale and Withania somnifera, against arthritis is discussed in this review.
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
PROBLEM TO BE SOLVED: To obtain the subject food and beverage high in activity scavenging active oxygen/free radical exerting undesirable influence on organisms and participating in various diseases and aging, preventing and reducing disorders related to the active oxygen/free radical by blending a food or beverage with a readily water-soluble flavonol glycoside. SOLUTION: A rutin, etc., are dispersed into water, mixed with naringinase, retained at pH7 to 5 hours at 50 deg.C, concentrated and cooled to precipitate isoquercitrin. The isoquercitrin is separated by filtration, dried, mixed with a corn starch and retained with a CTGase enzyme at pH6.8 for 12 hours. The prepared solution is passed through an adsorption resin column, the adsorbed substance is desorbed with 50vol.% aqueous solution of methanol and the desorbed substance is concentrated to dryness to give a readily water-soluble flavonol glycoside of quercetin-3-O-glycoside, etc. Then, a food is mixed 0.001-5wt. of the readily water-soluble flavonol glycoside to give the objective food or beverage having active oxygen/free radical scavenging activity.
Dahuang Huanglian Xiexin Decoction (DHXD) is the representative clinical formula for treating epigastric oppression. In this study, we aim to explore the effect of DHXD on obesity and attempt to investigate its potential mechanism. 3T3-L1 preadipocytes were differentiated and high-fat diet-induced obese rat model was established. DHXD was used for treatment and tunicamycin, the activator of endoplasmic reticulum (ER) stress, was adopted to investigate the related regulatory mechanism. Cell viability was evaluated using CCK-8 assay. Oil-Red O staining was performed to determine lipid accumulation. Glycerol production and Triglyceride content were measured using their commercial kits. Western blot was conducted to examine the expression of critical proteins. Results indicated that DHXD could greatly reduce intracellular lipid droplets and triglyceride in differentiated 3T3-L1 cells. Moreover, the elevated expression of mature adipocytes markers, PPARγ, aP2, during adipogenesis was decreased by DHXD treatment. In addition, DHXD aggravated the lipolysis in differentiated 3T3-L1 cells, as evidenced by the upregulated ATGL expression and the downregulated HSL expression. Besides, DHXD inhibited endoplasmic reticulum (ER) stress in 3T3-L1 cells. Further experiments indicated that the impacts of DHXD on adipocyte differentiation and lipid degradation were partly abolished by tunicamycin. Finally, DHXD alleviated lipid accumulation and ER stress in obese rats. In conclusion, DHXD ameliorates obesity via modulating adipocyte differentiation and lipid degradation through inhibiting ER stress.
OBJECTIVE/BACKGROUND: Chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA) and their comorbid association called Overlap Syndrome (OS) are frequent chronic diseases with high individual and societal burdens. Precise descriptions of the respective symptoms, comorbidities, and medications associated with these three conditions are lacking. We used a multidimensional phenotyping approach to identify relevant phenotypes characterizing these 3 disorders.
PATIENTS/METHODS: 308 patients with OSA, COPD and OS were prospectively assessed using a combination of body shape measurements and multidimensional questionnaires evaluating sleep, fatigue, depression and respiratory symptoms. Comorbidities and medications were confirmed by physicians. Patients made home blood pressure self-measurements using a connected wearable device to identify undiagnosed or uncontrolled hypertension.
RESULTS: Three distinct relevant phenotypes were identified. OSA patients were round in shape with a balanced waist-to-hip ratio, frequent witnessed apneas, nocturia, daytime sleepiness, depression, and high diastolic blood pressure. COPD patients had a thinner body shape with a high waist-to-hip ratio, complained mainly of fatigue, and exhibited a higher resting heart rate. OS patients were round in shape with a balanced waist-to-hip ratio, reported little sleepiness and depression, but had impaired sleep and the highest rate of cardio-metabolic comorbidities. Diminished fitness-to-drive was most apparent in patients with OSA and OS. Home blood pressure measurements identified undiagnosed hypertension in 80 % of patients and in nearly 80 % of those with hypertension it was uncontrolled by their current medications.
CONCLUSIONS: Our systematic multidimensional phenotyping approach identified distinct body shapes, symptoms, and comorbidity profiles among patients with OSA, COPD, and OS.